Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RM-718

Other · developed by Rhythm Pharmaceuticals

Phase 1/2 Most advanced trial
RYTM Developer
1 Registered trials

What is RM-718?

RM-718 is an investigational agent studied in multiple ascending doses in hypothalamic obesity and Prader-Willi syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Metabolic
Developer
Rhythm Pharmaceuticals, Inc. (RYTM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06239116 Phase 1/2 Hypothalamic Obesity Active not recruiting RYTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypothalamic ObesityPrader-Willi SyndromePWS

More from Rhythm Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RYTM page.

Follow RYTM, the company behind RM-718

See RYTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RYTM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.